What are the Key Drivers in the Immunoassays Market?

Increasing prevalence of evolving diseases and resistance to antibiotics means the demand for immunoassays is significantly to increase further in the future as they meet the demand for rapid and cost-effective diagnosis. Immunoassays are not only important to the identification of infectious diseases, but also crucial to many non-communicable diseases. This technology mainly uses non-communicable diseases, which are cardiovascular diseases such as heart attacks and stroke, cancers, chronic respiratory diseases like chronic obstructive pulmonary disease and asthma and diabetes. Numerous immunoassay technologies are presently used to identify such diseases.

• For Instance, In January 2025, SpinChip Diagnostics ASA, an innovative diagnostics company developing next generation Point of Care platforms for in vitro diagnostics, announced its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of NOK 1,624 million.
  

For more information, visit the Nova One Advisor website or email the team at ... | Call us: +1 804 420 9370

Growth Drivers for the Indian Immunoassay Market

The Indian immunoassay market is poised for robust growth due to several key factors:

Technological Advancements:

• CLEIA (Chemiluminescence Enzyme Immunoassay): This technology offers high sensitivity and specificity, making it highly effective for detecting low-abundance analytes. This is especially important for early-stage disease detection, such as cancers or rare conditions, driving demand in diagnostic settings.
• AI and Machine Learning: Integration of AI helps in the interpretation of immunoassay results, improving diagnostic accuracy and reducing human error. This enhances clinical decision-making, enabling better patient outcomes.

Rising Disease Burden:

• Non-communicable diseases (NCDs): The increasing prevalence of NCDs like diabetes and cancer is boosting the need for regular testing and monitoring, increasing the demand for immunoassay tests.
• Infectious diseases: The prevalence of diseases like tuberculosis, hepatitis, and emerging infectious diseases further drives the demand for rapid, accurate diagnostic tests.

Expanding Healthcare Infrastructure:

• Government initiatives like Ayushman Bharat are improving healthcare accessibility and affordability, particularly in rural regions, facilitating wider adoption of immunoassays.
• Increased investment in diagnostic facilities and healthcare infrastructure encourages the use of advanced technologies such as CLEIA, offering better diagnostic tools for medical professionals.

Growing Health Awareness:

• The rise in preventive healthcare and the emphasis on early disease detection are encouraging more individuals to seek regular check-ups, creating a sustained demand for immunoassay tests in clinics and hospitals.
  

Favorable Regulatory Environment:

• Government policies supporting local manufacturing, like the Make in India initiative, are driving the growth of domestic production of diagnostic equipment. This not only makes advanced technologies more accessible but also reduces costs, making immunoassay tests more affordable and widespread.
  

Rise of Personalized Medicine:

• Immunoassays play a crucial role in personalized medicine biomarkers
  

  Importance of Immunoassays in Indian Healthcare

  Immunoassays are central to the evolving landscape of Indian healthcare due to their wide-ranging applications:

  • Early Disease Detection
    

  Immunoassays allow for the early detection of diseases, enabling timely intervention and better patient outcomes.

  • Disease Monitoring
    

  They are crucial in monitoring disease progression and evaluating the effectiveness of treatments, particularly for chronic diseases like diabetes and cancer.

  • Public Health Impact
    

  Immunoassays are extensively used in large-scale public health programs for screening and monitoring infectious diseases, such as HIV and malaria.

  • Support for Research and Development
    

  Immunoassays play a significant role in drug development and vaccine research, helping to accelerate innovation in the pharmaceutical industry.

  • Accuracy and Reliability
    

  Technologies like CLEIA have raised the bar for diagnostic accuracy, reducing false positives and negatives, and increasing trust in diagnostics.

  What are the Ongoing Trends in the Immunoassays Market?

  • In June 2025, Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced that the HD-X Simoa Immunoassay Analyser has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems.
  • In June 2025, Revvity, Inc. announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalisation.
  • In July 2025, Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, announced the commercial launch of its SPEAR UltraDetect immunoassay solution. It delivers unparalleled sensitivity, specificity, precision, and scalability for robust biomarker measurement. The initial launch includes four assays, targeting key neurology biomarkers: phosphorylated tau 231 (pTau231), phosphorylated tau 217 (pTau217), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).
    

  What is the Emerging Challenge in the Immunoassays Market?

  Immunoassays are extensively used for therapeutic drug monitoring of different immunosuppressants. A main limitation of these immunoassays is their significant cross-reactivity with numerous metabolites of these agents. Key challenges include non-specific protein binding, non-specific relations within the immunoassays, infrequent insufficient reproducibility, comparatively long assay times, and photobleaching, which limits the growth of the market.

  By Regional Analysis

  Why did North America Dominate the Market in 2024?

  By capturing a major share, North America registered dominance in the market in 2024, as this region has widespread and sophisticated laboratory networks, advanced diagnostic technology, and a well-established healthcare diagnostics infrastructure. The growing rates of chronic conditions such as cancer and infectious diseases drive the demand for precise and effective analytical tools, where immunoassays play a significant role, which contributes to the growth of the market.

  • For Instance, In January 2025, bioMérieux acquired 100% ownership of SpinChip for a total enterprise value of €138m. The cash out will amount to approximately €111m since bioMérieux already owns 20% of the shares of SpinChip.
    

  How did the Asia Pacific Grow Notably in the Market in 2024?

  During 2025-2034, the Asia Pacific is anticipated to expand at a rapid CAGR in the immunoassays market as the growing pharmaceutical biotechnology

  • For Instance, In September 2025, Beckman Coulter introduces the automated BD-Tau assay for clinical research. The new test is available on the DxI 9000 and Access 2 Analysers, along with a range of neurodegenerative disease RUO assays.
    
  Immediate Delivery Available | Buy This Premium Research (Global Deep Dive USD 3800)

  Segmental Insights

  By Product Analysis

  Which Product Led the Immunoassays Market in 2024?

  The reagents and kits segment accounted for the dominating share of the market in 2024, as immunoassay reagents and kits have been used for decades to enable the generation of consistent and reproducible data with lower up-front optimisation. They used to identify proteins, nucleic acids, lipids or small molecule targets, as long as there are known antibodies that bind precisely to that target. Profitable kits and reagents undergo rigorous quality control (QC) and validation by dedicated manufacturers.

  Whereas the analysers segment is predicted to register rapid expansion in the forecasting period, as immunoassay analysers with high throughput that are standard for large laboratories with high HbA1c volumes. Immunoassay analysers process a large number of samples in a limited period of time, lowering the turnaround time for outcomes. Immunoassay analysers with automation abilities rationalise workflows, making them crucial in healthcare and research settings.

  By Technology Analysis

  How did the ELISA segment dominate the market in 2024?

  In 2024, the ELISA segment captured the biggest share of the immunoassays market, as ELISA has great sensitivity due to an enzyme as a reporting group. This is a small portion which could cause reactions for the production of the chromogenic reaction phenomenon. ELISA kits make it a more favoured biotechnical device for a broad range of applications. It is helpful for both the healthcare diagnosis of diagnostic conditions or diseases and scientific research. ELISA tests are eco-friendly and safe to the evasion of radioactive substances and major amounts of organic solvents.

  Although the chemiluminescence immunoassay segment will expand fastest during 2025-2034, as the chemiluminescent immunoassay analyser removes the application of radioactive substances. It has exclusive properties of high sensitivity, speed, and high specificity, precision, specificity, and automation. Chemiluminescence immunoassay

  By Application Analysis

  How did the infectious diseases dominate the Market in 2024?

  The infectious diseases segment held the biggest share of the immunoassays market in 2024, as infectious disease immunoassays play a significant role in detecting and identifying various pathogens that pose a risk to human health. These assays utilise the body's immune response to identify the presence of specific antibodies or antigens related to infectious agents. The immune system produces antibodies in response to the presence of external substances, such as viruses, bacteria, or other pathogens.

  By End-User Analysis

  How did the hospitals & clinics dominate the Market in 2024?

  The hospitals and clinics segment held the biggest share of the immunoassays market in 2024, as immunoassays are regularly applied for healthcare diagnostics, therapeutic drug monitoring, biopharmaceutical

  By Specimen Type Analysis

  How did the blood dominate the Market in 2024?

  The blood segment held the biggest share of the immunoassays market in 2024, as immunological analysis apparatus has greatly amplified the specificity and sensitivity of the analysis index, and significantly enhanced the accuracy and effectiveness of the test. This test has a high sensitivity and detects antigens at picogram levels.

  Immunoassays Market Companies

  • Thermo Fisher Scientific – Thermo Fisher provides a comprehensive portfolio of immunoassay reagents, kits, and automated analyzers, supporting clinical diagnostics and research applications globally. The company invests heavily in R&D to introduce innovative immunoassay technologies that enhance sensitivity and throughput.
  • Roche Diagnostics – Roche is a leading player offering high-quality immunoassay instruments, reagents, and testing platforms for hospitals, laboratories, and pharmaceutical research. Its strong focus on automation and digital integration ensures accurate and efficient diagnostics, reinforcing its market dominance.
  • Abbott Laboratories – Abbott develops advanced immunoassay platforms, including point-of-care and laboratory-based solutions, for infectious diseases, oncology, and hormonal testing. The company emphasizes innovation, reliability, and rapid diagnostics, driving adoption across clinical and research settings.
  • Siemens Healthineers – Siemens provides a range of immunoassay analyzers, reagents, and diagnostic solutions with high throughput and accuracy. Its global presence and strong service network support widespread adoption in hospitals and laboratories.
  • Bio-Rad Laboratories – Bio-Rad specializes in immunoassay kits, reagents, and quality control solutions for clinical diagnostics and life sciences research. Its focus on high-quality and validated products enhances precision and reliability in diagnostic testing.
  • Beckman Coulter – Beckman Coulter offers immunoassay analyzers, reagents, and automation solutions for clinical laboratories and research institutions. The company supports efficiency and accuracy with scalable solutions and comprehensive after-sales services.
  • GE Healthcare – GE Healthcare provides immunoassay analyzers and reagents that integrate advanced imaging and diagnostic technologies. Its solutions focus on enhancing laboratory workflows and improving diagnostic outcomes worldwide.
  • DiaSorin S.p.A. – DiaSorin develops innovative immunoassay kits and analyzers for infectious diseases, oncology, and autoimmune disorders. Its strong R&D capabilities ensure high sensitivity and specificity, boosting its adoption in clinical diagnostics.

  What are the Recent Developments in the Immunoassays Market?

  • In September 2025, Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio of neurodegenerative disease RUO assays, is available for use on the groundbreaking DxI 9000 Immunoassay Analyser and Access 2 Analyser.
  • In September 2025, GE HealthCare enters an agreement to acquire icometrix; Beckman Coulter Diagnostics launches the industry's first fully automated brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test
  • In January 2025, SpinChip Diagnostics ASA, an innovative diagnostics company developing next-generation Point of Care platforms for in vitro diagnostics, announced its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of NOK 1,624 million.
  • In March 2025, Gentian Diagnostics announced the launch of the GCAL Calprotectin Immunoassay with Beckman Coulter Diagnostics to its clinical chemistry platforms. This collaboration illustrates our commitment to enhancing diagnostic efficiency for improved treatment decisions.

  More Insights in Nova One Advisor:

  • Recombinant Peptide Market - The global recombinant peptide market size
  • Loratadine API Market - The global loratadine API market size
  • Spirulina Market - The global spirulina market size
  • Telehealth 2.0 Market - The global telehealth 2.0 market
  • Homeopathy (Homeopathic Medicine) Market - The global homeopathy (homeopathic medicine) market size
  • AI In Radiology Market - The global AI in radiology market size
  • Cosmetic Surgery And Procedure Market - The cosmetic surgery and procedure market size
  • Generic Drugs Market - The global generic drugs market size
  • Precision Psychiatry Market - The global precision psychiatry market size
  • Gene Therapy Media Market - The global gene therapy media market
  • Stereotactic Surgery Devices Market - The global stereotactic surgery devices market size
  • Transdermal Scopolamine Market - The global transdermal scopolamine market size
  • Anal Fistula Drugs Market - The global anal fistula drugs market
  • Active Pharmaceutical Ingredients CDMO Market - The global active pharmaceutical ingredients CDMO market size
  • Oncology Information Systems Market - The global oncology information systems market size
  • Radiation Oncology Market - The global radiation oncology market size

  Immunoassays Market Report Segmentation

  This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. For this study, Nova One Advisor has segmented the global immunoassays market

  By Product

  • Reagents & Kits
  • Analyzers/Instruments
  • Software & Services
    

  By Technology

  • ELISA
  • Rapid Tests
  • Chemiluminescence Immunoassay (CLIA)
  • Radioimmunoassay (RIA)
  • Fluorescence Immunoassay (FIA)
    

  By Application

  • Infectious Diseases
  • Oncology
  • Cardiology
  • Autoimmune Disorders
  • Endocrinology & Hormonal Disorders
  • Toxicology & Drug Testing

  By End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Pharmaceutical & Biotechnology Companies

  By Specimen Type

  • Blood
  • Urine
  • Saliva
  • Other Fluids

  By Regional

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
    
  Immediate Delivery Available | Buy This Premium Research Report (Global Deep Dive USD 3800)

  About-Us

  Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.

  Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.

  Our Trusted Data Partners

  Towards Chemical and Materials | Precedence Research | Statifacts | Towards Packaging | Towards Healthcare | Towards Food and Beverages | Towards Automotive | Towards Consumer Goods | Nova One Advisor | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics | Towards Chem and Material
  Web:

  Contact Us

  USA: +1 804 420 9370

  Email: ...
  For Latest Update Follow Us: LinkedIn